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1150Abstract: Opioid misuse, abuse, and overdose are a rapidly growing public health epidemic. Medicaid
Lock-In Programs (MLIPs) are designed to prevent overutilization of controlled substances by Medicaid
patients. However, despite widespread use, there is little information on their effect. Using North Car-
olina (NC) Medicaid claims data from October 2008 through June 2013, we examined changes in
Medicaid-reimbursed opioid prescriptions by patients enrolled in NC’s MLIP. We used mixed effects
models to examine the effect ofMLIP enrollment onmonthly opioid claims, number of pharmacies, total
days’ supply, total units (ie, pills), and total Medicaid payments for opioids. In our sample of 6,148 MLIP
patients, the odds of having any opioid claim in a given month was 84% lower during MLIP enrollment
relative to the period before enrollment (odds ratio = .16). MLIP enrollment also corresponded with a
reduction in monthly number of opioid prescriptions by 1.13, monthly number of pharmacies by .61,
and monthly Medicaid expenditures by $22.78. AlthoughMLIPs may constitute a successful component
of comprehensive efforts to reduce the potential overutilization of opioids, care should be taken to
ensure thatprogramssuchasMLIPsdonot constrainpatients’ legitimateneeds foranalgesicmedications.
Perspective: Enrollment in NC’s MLIP reduced the likelihood that patients would present a claim for
anopioid prescription, and the number of opioid prescriptions patients secured eachmonth.MLIPsmay
constitute a successful strategy for reducing the misuse, abuse, and diversion of prescription opioids.
However, further research is needed to examine the program’s potential unintended consequences.
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.doi.org/10.1016/j.jpain.2016.07.003morbidity and mortality.24 Sales of prescription opioid
analgesics increased by >300% between 1999 and 2010,
duringwhich time the number of overdose deaths attrib-
uted to prescription opioids increased by 312%.5,18
According to the Centers for Disease Control and
Prevention, in 2014 >47,000 deaths were attributed to
drug overdose in the United States in 2014, 19,000 of
which involved prescription opioids.23 An even greater
number of people survive unintentional overdoses, lead-
ing to impairments, disabilities, and dependency. In
addition to the human toll, the misuse and abuse of pre-
scription opioids results in $53 to $56 billion in societal
Skinner et al The Journal of Pain 1151costs each year.3,12 This burden falls on the health care
system and state resources, including law enforcement.12
Patients’ use of multiple prescribers presents a difficult
issue for their physicians, who must navigate changing
dosages and potentially risky drug interactions, while
also providing compassionate care and working to
manage chronic pain.16 Increased prescribing of and
greater access to opioids has also led to a range of abuses
and dangerously uncoordinated care for many patients.8
Recent analyses of Medicare data indicated that patients
prescribed opioids had an average of 52 prescriptions
per year from approximately 10 drug classes (ie, opioid
prescriptions, aswell as other prescriptions), riskingmulti-
ple drug interactions.19 Moreover, research has suggested
that opioid prescribing by multiple prescribers is not only
a common practice but is also associated with increased
rates of opioid-related hospital admissions.14 Even in the
absence of diversion or other illicit use, continuity of
care is critical to addressing the misuse of opioids.
The misuse and abuse of opioids, as well as other
controlled substances (CSs) including benzodiazepines,
has led many states to develop programs that seek to
reduce CS abuse and to improve continuity of care for
those needing CS medication therapy. In part because
mortality from overdoses in the Medicaid-eligible popu-
lation is 5 to 7 times that of the general population,9 and
in part because opioid misusers are more likely to be
covered by Medicaid,2 states are increasingly managing
CS abuse bymeans ofMedicaid Lock-In Programs (MLIPs).
MLIPs are designed to identify Medicaid patients at risk
of health-related issues caused by the potential overuti-
lization of CS and tightly regulate their access, generally
by requiring that patients use a single prescriber and/or
pharmacy to obtain certain CS prescriptions for a speci-
fied period of time. The use of MLIPs has been recom-
mended by the Centers for Medicare and Medicaid
Services (CMS).6 Specifically, the CMS recommends
including providers and pharmacies in MLIPs, because
this helps to improve the monitoring of CS use across
multiple points in the health care system.
The North Carolina (NC) Recipient Management MLIP,
implemented in October 2010,10 was developed in
response to aUSGovernment Accountability Office audit
that reported that NC was 1 of 5 states with an unusually
large number of claims for CS prescriptions.26 The NC
MLIP was intended to reduce fraudulent prescription
claims for opioids and antianxiety CS medications, while
improving continuity of treatment among patients with
high utilization of CS prescriptions. Additionally,
because of the known association of dependency and
overdose with an individual’s total number of prescrip-
tions and the number of providers from whom they
secure prescriptions,11 the NC MLIP may result in signifi-
cant improvements in care utilization, health outcomes,
and quality of life.
Despite thewidespread use ofMLIPs, little information
can be found in the published literature that directly as-
sesses their outcomes.22 To date, programs like the NC
MLIP have been developed from a paradigm focusing
on cost savings, with improved health outcomes seem-
ingly considered as a secondary benefit. Recently, theUS Senate voted in favor of S.524, the Comprehensive
Addiction and Recovery Act of 2016, which includes a
provision for lock-in programs in Medicare.25 If enacted,
such a provision would have a sweeping effect on many
Medicare beneficiaries. Current research provides mini-
mal insight into the effect, positive or negative, of MLIPs
on patients.
Because of the need to better understand the effects
of MLIPs on prescription drug utilization, we sought to
identify changes in the number of Medicaid-
reimbursed opioid prescriptions filled, and the number
of pharmacies from which these prescriptions were ob-
tained, by individuals participating in the NC MLIP.
Among patients enrolled in the MLIP, we hypothesized
that we would find reductions in the number of 1) pre-
scriptions for opioids this population filled and 2) phar-
macies each enrollee visited for the opioid prescriptions
they received while enrolled, compared with the period
before enrollment.Methods
This study was approved by the Institutional Review
Board at the University of NC at Chapel Hill. The require-
ment for individual informedconsentwaswaivedbecause
this study used existing administrative claims data.Overall Design
This study was a single group, interrupted time series
design of individuals enrolled in the MLIP at any point
during the 33 months after the program’s implementa-
tion on October 1, 2010. We analyzed Medicaid-
covered prescription drug utilization over a 57-month
period (October 1, 2008–June 30, 2013) encompassing
24 months before (October 1, 2008–September 30,
2010) through 33 months after (October 1, 2010–June
30, 2013) NC MLIP implementation. The population
eligible for Medicaid, enrollment in the MLIP, and pre-
scription fill and provider utilization outcomes were as-
sessed for each calendar month, beginning on the first
day of the month and ending with its last day.Data Source
Our data were comprised of NC Medicaid claims pro-
vided by the NC Division of Medical Assistance, which
manages the State’s Medicaid program. Data were struc-
tured to provide total opioid prescriptions according to
month for each Medicaid-enrolled individual. Any given
individual could have provided up to 57 months of data.
To ensure that pre-MLIP enrollment data were limited to
themonths when an individual was ‘‘at risk’’ of an opioid
prescription, we excluded all months before the individ-
ual’s first month in which Medicaid paid for an opioid
prescription they filled. For example, if an individual
only began receiving opioid prescriptions after a specific
event, this would exclude the time period before the
onset of opioid use. To ensure we did not capture resid-
ual and potentially altered effects related to disenroll-
ment from the MLIP, we excluded any months after an
individual was no longer enrolled in the program.
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The NC Division of Medical Assistance enrolled pa-
tients in the MLIP on a monthly basis. Program staff
determined MLIP eligibility on a monthly basis by exam-
ining the number of opioid and benzodiazepine pre-
scriptions filled and the number of providers from
which such prescriptions were obtained in the previous
2 months. Specifically, patients were eligible for enroll-
ment if in a consecutive 2-month period they obtained
more than 6 opioid prescriptions, obtained more than
6 benzodiazepine prescriptions, or received opioid or
benzodiazepine prescriptions from more than 3 unique
prescribers.Medical histories of eligible patients were re-
viewed by MLIP staff, and patients with certain diagno-
ses (eg, cancer, terminal illnesses) were determined
exempt from enrollment. Approximately 200 patients
were enrolled in the MLIP each month. Enrolled patients
were restricted to using 1 prescriber and 1 pharmacy
location to obtain their opioids and other specific CS pre-
scriptions for a 12-month period. After the 12-month
period, patients were disenrolled from the MLIP.
Our initial sample included 6,221 individuals (repre-
senting 445,549 claims) who were enrolled in the MLIP
at any time between October 2010 and June 2013, inclu-
sive. We excluded a small number of individuals who
were younger than 18 or older than 65 years at the
time of enrollment (n = 17), or who were not in a private
living environment (n = 38), to avoid confounding fac-
tors of dual eligibility and differing care environments.
Because our goal for this analysis was to examine
changes in opioid prescriptions, we also excluded indi-
viduals who received only benzodiazepine prescriptions
(n = 18), and were thus enrolled in theMLIP on that basis
alone.Measures
The primary exposure for this analysis was enrollment
in theMLIP, which we assessed eachmonth. Outcomes of
interest included various measures related to the utiliza-
tion of opioids, which were defined by Medicaid using
specific therapeutic and generic class codes. Specifically,
we used the First Data Bank therapeutic class codes:
H3A, H3H, H3J, H3M, H3N, H3U, and H3X, and excluded
generic codes for tramadol: 07221, 26387, 50417,
50427, 13909, because tramadol was not included under
MLIP restrictions until after our study period ended. We
used these codes to create an indicator of whether a
given claim represented an opioid, and then added these
within enrollees to create a total number of opioid pre-
scriptions for each individual according to month. Using
these indicators, we also created total values for each en-
rollee for the monthly amount paid by Medicaid for
these prescriptions, as well as the days’ supply obtained
and units (ie, pills) dispensed.
Pharmacies were identified by their unique identifica-
tion number in Medicaid claims data. We identified the
first instance of each unique pharmacy according to
month, then summed these to create a total number of
pharmacies each individual visited to obtain Medicaid-
reimbursed opioid prescriptions each month.Covariate information included individual-level data
fromMedicaid claims (age, sex, race, ethnicity, and living
arrangement) and county-level data, which included
prescriber and pharmacy density. Prescriber density was
defined as the number of actively practicingmedical pro-
fessionals, including physicians, physician assistants, and
nurse practitioners, who had CS prescribing authority in
each patient’s county of residence. The number of
actively practicing medical professionals was obtained
from the 2010 NC Health Professions Data file and was
linked to each patient’s county of residence in his or
her Medicaid data.21 Pharmacy density was defined as
the number of licensed community and outpatient phar-
macies in each patient’s county of residence. The number
of pharmacies was obtained from the CMS National Pro-
vider Identifiers 2012 master file.7Analysis
We used mixed effects models that took advantage of
the longitudinal nature of the data. Our models differed
depending on the outcome, but all allowed for varying
numbers of months in the period before and during
MLIP enrollment, as well as for months with no data
(ie, for months in which an individual was not enrolled
in Medicaid). Our models provided an average effect of
enrollment in the MLIP on each of the outcomes speci-
fied previously, controlling for individual and county-
level covariates. For the binary outcome of any opioid
prescription in a month, we used generalized least
squares logistic regression models with random effects
to account for within-person correlation over time. For
the nonbinary (ie, continuous, count) outcomes, we
also used mixed effects models with random effects but
used restrictedmaximum likelihood estimation and spec-
ified an autoregressive correlation structure on the error
terms. We considered Poisson mixed effects models for
the count variables (ie, number of prescriptions and
pharmacies). However, the resulting effect size estimates
for the Poisson models were nearly equivalent to those
obtained when we used the linear mixed effects models.
Therefore, because of the easier interpretation of linear
parameters, we chose these models for all nonbinary
outcomes. All models included fixed effect terms for
months to control for population trends over time.Results
Our final sample included 6,148 NC MLIP enrollees
who collectively had 211,666 months of data during
our study period. The mean age of MLIP participants at
their time of enrollmentwas 35 years, and theywere pre-
dominantly female (69%) and white (78%).
Almost two-thirds (64%) of all enrollees’ months
included at least 1 claim for an opioid (Table 1). The num-
ber of months including at least 1 opioid claim differed
markedly before (70%) and after (47%) a participant’s
enrollment in the MLIP. The mean number of opioid pre-
scription claims (including months with no prescriptions)
was 1.62 before enrollment in the MLIP and .84 after
enrollment. We also found reductions in the mean
Table 1. Average Number and Characteristics of Prescription Opioids Dispensed to Patients Per
Month During Pre-Enrollment and Enrollment Periods in the NC MLIP (NC Medicaid Claims Data,
October 2008–June 2013)
OVERALL (SD) PRE-ENROLLMENT IN MLIP (SD)* DURING MLIP ENROLLMENT (SD)*
Any opioid claim per mo, % 64.2 (47.9) 69.9 (45.9) 46.9 (49.9)
Mean opioid claims per mo 1.43 (1.56) 1.62 (1.63) .84 (1.16)
Mean pharmacies used per mo .84 (.81) .95 (.85) .48 (.53)
Mean total days’ supply received per mo 22.41 (26.27) 23.36 (26.20) 19.48 (26.27)
Mean total units received per mo 85.13 (119.73) 90.59 (121.67) 68.31 (111.88)
Mean total Medicaid payments per mo, $ 102.88 (396.25) 99.60 (400.96) 112.99 (381.20)
*All differences between pre-MLIP enrollment and MLIP-enrollment periods had P < .001.
Skinner et al The Journal of Pain 1153number of pharmacies used, mean total days’ supply
received, and mean total units dispensed during MLIP
enrollment, compared with before enrollment.
Inmultivariable analysis, the odds of having any opioid
claim in a given month was 84% lower during MLIP
enrollment relative to the period before enrollment
(adjusted odds ratio = .16; 95% confidence interval [CI],
.15–.16; Table 2). Enrollment in the MLIP also corre-
sponded with a reduction in the number of opioid pre-
scriptions participants secured each month by 1.13
(95% CI, 1.16 to 1.11), the number of pharmacies
they visited each month by .61 (95% CI, .62 to .60),
and total Medicaid payments per month by $22.78
(95% CI, $27.88 to $17.69). Reductions in total days’
supply received and total units dispensed per month
were also observed.Discussion
Confirming our study’s hypotheses, we found that
enrollment in the MLIP resulted in reductions in the
average of the number of opioid prescriptions filled
per month and the number of pharmacies visited to
obtain those prescriptions. After accounting for key indi-
vidual and county-level covariates, we found that the
odds of having an opioid prescription in any given
month while enrolled in the program was 84% lower
than before enrollment.We also found that eachmonth,Table 2. Unadjusted and Adjusted Estimates Comp
Measures Between Pre-Enrollment And Enrollmen
Data, October 2008–June 2013)
ESTIMATEy S
Odds ratio for having any opioid claim in a mo .23 .0
Mean difference in number of opioid claims per mo 1.15 .0
Mean difference in number of pharmacies used per mo .62 .0
Mean difference in total days’ supply received per mo 9.92 .1
Mean difference in total units received per mo 41.22 .8
Mean difference in total Medicaid payments per mo 23.50 2.5
Abbreviations: SE, standard error; CI, confidence interval.
*Adjusted analyses control for individual-level (ie, race, ethnicity, sex, age, and living
yP < .001 for all effect estimates.on average, patients received approximately 1 fewer
opioid prescription and visited fewer pharmacies to
obtain these opioids. As expected, these differences
further corresponded with reductions in the total days
of supply received (mean difference: 9.6) and the total
units dispensed (mean difference: 40.3) each month.
Finally, our study showed that theMLIP reduced the pro-
gram’s drug costs by an average each month of $22.78
per MLIP patient. These findings would appear to pro-
vide clear evidence of the program’s effectiveness in
reducing Medicaid-covered opioid prescriptions, at least
in NC.
The large reduction in the odds of filling any prescrip-
tion for opioids after enrollment in the NC MLIP raises
questions about whether enrollees were denied access
to needed medications. Concerns have been expressed
that restrictions on MLIP participants’ access to providers
and dispensers—particularly providers—may lead to
needless and preventable suffering. For example, partic-
ipants may receive CS prescriptions from providers with
different specialties (eg, from psychiatrists and orthope-
dists) for entirely defensible reasons, one relating to
mental health and theother for painmanagement. There
is also legitimate reason for concern that MLIP enrollees
who experience acute incidents before the scheduled
closing of their designated provider’s office or pharmacy
(eg, for a long holiday weekend) may suffer needlessly,
especially if they lack access to emergency care. There isaring Changes In Monthly Opioid Utilization
t Periods in the NC MLIP (NC Medicaid Claims
UNADJUSTED ADJUSTED*
E 95% CI ESTIMATEy SE 95% CI
03 .23–.24 .16 .003 .15–.16
12 1.18 to 1.13 1.13 .013 1.16 to 1.11
06 .63 to .61 .61 .006 .62 to .60
89 10.29 to 9.55 9.62 .190 9.99 to 9.25
80 42.95 to 39.50 40.31 .888 42.05 to 38.57
58 28.52 to 18.49 22.78 2.599 27.88 to 17.69
arrangement) and county-level (ie, prescriber and pharmacy density) covariates.
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enrollees, and particularly the effects of enrollment on
their quality of life and their access to CSs in response
to legitimate needs. The guiding principle of primum
non nocere applies here as it does to all other aspects
of the health care system; particularly because of the rela-
tive vulnerability of Medicaid populations.17
Recent pilot programs supported by the Association for
Community Affiliated Health Plans may provide a starting
point for research and evaluation on enhanced MLIP
models with the potential to better serve patient needs.1
Specifically, 2 enhanced MLIP pilot programs integrated
into Medicaid managed care plans in New Jersey and
Ohio took innovative approaches of building comprehen-
sive case management care for those enrolled. For
example, recognizing that MLIP patients often have a
range of unmet health- and quality of life-related needs,
casemanagers in a New JerseyMedicaid health plan assess
MLIP patients’ pain management care and evaluate their
critical resource needs (eg, food, transportation, andhous-
ing). In Ohio, the largest Medicaid managed care plan in
the state integrated a case management ‘‘wraparound’’
with its MLIP. This ‘‘wraparound’’ component similarly in-
volves case managers who work closely with patients to
address a full range of patient needs, connecting them
with community resources, social services, and health
careprofessionals. Additionally, casemanagers are trained
in strategies designed to help build long-term, supportive
relationships with patients, including helping them
acknowledge potential substance abuse issues and
engage in treatment as appropriate. Further research on
these and other MLIP models that work to address all pa-
tient needs are warranted to optimize outcomes from the
perspectives of patients, providers, and Medicaid.
The US Senate has recently approved a bill supporting
lock-in programs for Medicare.25 Our findings suggest
that although such a policy might reduce costs, there
maybeunintendedconsequences.Assessing the full effect
of such programs is essential to ensuring patients receive
needed care. Additionally, further research on the effect
of programs designed to reduce prescription opioid
misuse on the concurrent increase in heroin use and over-
dose is warranted because of the recent secondary
epidemic of heroin use and overdose and the widespread
reporting by heroin users their opioid use was initiated
with prescription opioids.13,15,20 Research on the extent
to which MLIP restrictions affect or trigger illicit opioid
use could include urine toxicological screening data on
patients, behavioral interviews, and/or a more complete
assessment of dispensed prescription medications using
prescription drug monitoring program data.Limitations
We acknowledge several limitations to this study.
First, we relied exclusively on the claims data that are
available to program administrators. These do not cap-
ture any outside sources of opioid prescriptions, such as
participants who pay dispensers in cash. Second, as a
single group longitudinal study in which each partici-
pant serves as his or her own control, we cannot exclude
the possibility that our findings may reflect either cur-
rent secular trends or regression to the mean. The latter
source of bias is particularly problematic in that MLIP
enrollees are identified for lock-in because they ex-
ceeded a state-defined threshold of high opioid utiliza-
tion. However, the staggered enrollment across the first
2 years of the program should reduce the impact of any
secular trends on MLIP effect. Our analysis also only
examined individuals younger than 65 years of age.
Although this is appropriate because of the near-
universal Medicare coverage in this age group, our find-
ings may differ for other populations, such as older
Medicare enrollees. Finally, we are unable to identify
‘‘doctor-shopping’’ in these claims, which would pro-
vide additional context to the patterns of prescriptions.
Prescriber identification is not a required field for sub-
mission of pharmacy claims, and extensive missing
data did not allow for a reliable indicator of each pre-
scription’s prescriber.
Conclusions
The misuse and abuse of prescription drugs, particu-
larly opioids, has become a problem at all levels of the
health care system. Misuse can result in excessive use of
medical services, and the costs of these opioid medica-
tions often represent one of the largest portions of
Medicaid pharmacy expenditures.4 MLIPs may constitute
a successful component of comprehensive efforts to
reduce misuse of opioids and other prescription medica-
tions. Care should be taken, however, to ensure that pro-
grams, such as MLIPs, do not constrain patients’
legitimate needs for analgesic medications. Additional
research will also need to examine the extent to which
individuals react to the restriction of MLIPs by obtaining
opioids without using Medicaid coverage, or through
illicit means.
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